Ai-Media Technologies Ltd
AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.
相关临床试验
12
1 进行中
药物批准
2
批准总数
监管机构
1
监管机构数
成立时间
1990
已完成
5
41.7%
尚未招募
1
8.3%
招募中
1
8.3%
暂停
1
8.3%
Temporarily Not Available
1
8.3%
终止
3
25.0%
- AIM ImmunoTech is positioning its lead drug Ampligen as a potential treatment for Ebola virus disease amid the WHO's declaration of a Public Health Emergency of International Concern for the Bundibugyo strain outbreak. - Pre-clinical studies conducted at USAMRIID Biosafety Level 4 laboratories demonstrated 100% survival protection in mice following lethal Ebola virus exposure when Ampligen was administered early after infection. - The company plans to release findings on Ampligen's potential as an early treatment for Ebola virus disease, highlighting its mechanism as a TLR3 agonist that blocks viral dsRNA binding. - Ampligen has received Orphan Drug designation for Ebola virus disease from both the FDA and European Medicines Agency, positioning it for potential development as a countermeasure against emerging viral threats.
- AIM ImmunoTech has secured a Japanese patent covering Ampligen (rintatolimod) in combination with checkpoint inhibitors for cancer treatment, valid until December 20, 2039. - The patent encompasses multiple cancer types including pancreatic, ovarian, breast, lung, and colorectal cancers, strengthening AIM's intellectual property portfolio in Japan's third-largest global pharmaceutical market. - AIM is currently conducting Phase 2 trials combining Ampligen with checkpoint inhibitors, including a collaboration with AstraZeneca for metastatic pancreatic cancer showing promising survival benefits. - The company believes this novel combination approach could revolutionize treatment for historically challenging cancers through synergistic therapeutic effects.
- AIM ImmunoTech announced publication of a peer-reviewed study in the Journal for ImmunoTherapy of Cancer demonstrating positive combination effects of Ampligen and interferon-alpha on tumor growth and survival. - The research concluded that systemic chemokine modulation can eliminate PD-1 resistance in cold tumors, suggesting intratumoral cytotoxic T-lymphocyte accumulation is the key limiting factor for immune checkpoint inhibitor effectiveness. - The findings indicate broad therapeutic potential for tumor microenvironment reprogramming strategies in cancer immunotherapy.
- Preliminary data from the DURIPANC Phase 2 trial shows 21% of metastatic pancreatic cancer patients achieved progression-free survival exceeding 6 months with rintatolimod plus durvalumab combination therapy. - The combination demonstrated a favorable safety profile with no significant toxicity in 14 enrolled patients who had previously received FOLFIRINOX chemotherapy. - Early survival data indicates 64% of patients achieved overall survival greater than 6 months, outperforming historical benchmarks in this aggressive disease setting. - The trial represents a collaboration between AIM ImmunoTech, AstraZeneca, and Erasmus Medical Center, targeting a patient population with limited treatment options.
- AIM ImmunoTech's Phase 2 DURIPANC study evaluating Ampligen combined with AstraZeneca's Imfinzi shows encouraging safety and efficacy signals in metastatic pancreatic cancer patients post-FOLFIRINOX treatment. - The combination therapy demonstrated no significant toxicity with 21% of patients achieving progression-free survival greater than 6 months and 64% of patients surviving beyond 6 months. - The study builds on previous monotherapy data from over 50 patients treated under compassionate use, representing a potential breakthrough in a disease with historically limited immunotherapy responsiveness. - Results suggest superior outcomes compared to historical data for maintenance or second-line immunotherapies in pancreatic cancer, a disease that kills over 500,000 people worldwide annually.
- AIM ImmunoTech received U.S. patent No. 12312376 covering manufacturing methods for therapeutic double-stranded RNA products including Ampligen, extending protection until January 25, 2041. - The patent strengthens AIM's intellectual property portfolio for its first-in-class TLR3 agonist immunomodulator, which has demonstrated broad spectrum activity in clinical trials for cancers, viral diseases, and immune disorders. - Combined with existing patents and multiple FDA and EMA orphan drug designations, the manufacturing patent provides AIM extended development runway as it seeks regulatory approval for Ampligen across various indications.
- AIM ImmunoTech initiates development of Ampligen as a vaccine adjuvant for avian influenza, partnering with Amarex Clinical Research for IND application management. - Previous research at University of Alabama-Birmingham demonstrated Ampligen's ability to boost FluMist vaccine response four-fold and induce protection against multiple avian flu strains. - The company is pursuing collaborative grants to support a follow-up clinical study combining Ampligen with AstraZeneca's FluMist nasal vaccine.
- Safety Committee grants approval for Phase 2 portion of AIM ImmunoTech's Phase 1b/2 trial evaluating Ampligen in combination with AstraZeneca's Imfinzi for late-stage pancreatic cancer treatment. - The trial, conducted at Erasmus Medical Center in the Netherlands, addresses a critical unmet need in oncology, with pancreatic cancer claiming approximately 50,000 American lives annually. - The combination therapy aims to enhance immune system response through Ampligen's immune reprogramming properties alongside Imfinzi's checkpoint inhibition mechanism.
- AIM ImmunoTech's AMP-518 study results support Ampligen as a potential therapeutic for moderate-to-severe Post-COVID fatigue. - Patients treated with Ampligen in the AMP-518 trial showed improvement in the Six-Minute Walk Test (6MWT) compared to placebo. - A subset of patients with baseline 6MWT scores under 205 meters experienced a significant mean improvement of 139 meters with Ampligen. - AIM ImmunoTech plans to focus future trials on Ampligen's therapeutic potential for moderate or worse COVID-related fatigue or ME/CFS symptoms.
- AIM ImmunoTech highlights the continued development of Ampligen (rintatolimod) across multiple clinical programs targeting pancreatic cancer and Long-COVID. - Several key milestones are anticipated in the next 18 months, with trials partially funded by the National Cancer Institute, AstraZeneca, and Merck. - Positive preliminary data were reported from a Phase 1b/2 study of Ampligen and Imfinzi for late-stage pancreatic cancer, and Phase 2 data for post-COVID fatigue. - AIM ImmunoTech received patents for Ampligen in treating endometriosis and post-COVID fatigue, and completed cGMP manufacturing of 9,042 clinical vials.
